Abstract: Objective To evaluate the therapeutic effect of aerosol inhalation of BD-77 against mycoplasma pneumoniae (MP) infection in mice. Methods Balb/c mice were randomly divided into the normal control group, model control group, azithromycin control group (42 mg·kg^-1·d^-1), BD-77 high dose group (75 mg·mL^-1, 15 min), and BD-77 low dose group (37.5 mg·mL^-1, 15 min). The mouse model of mycoplasma pneumoniae pneumonia (MPP) was induced by intranasal infection with MP. After four consecutive days of aerosol inhalation, the therapeutic effect of BD-77 was evaluated based on the lung index, lung inhibition rate, and pathological changes of lung tissues. The contents of interleukin (IL)-6, IL-1β, tumor necrosis factor α (TNF-α) in lung tissues and the level of C reactive protein (CRP) in serum were also detected using ELISA method. Results Both doses of BD-77 aerosol administration could decrease the lung index and the release of IL-6, IL-1β and TNF-α in lung tissues, ameliorate pulmonary inflammation and reduce serum CRP levels. Conclusion Aerosol inhalation of BD-77 preparation is effective for MPP in mice. This study provides data for the development of BD-77 as a drug for prevention and treatment of MPP.

Key words: BD-77, mycoplasma pneumoniae, aerosol inhalation, inflammatory factor, lung index, lung inhibition rate, mouse